Regencell Bioscience Completes 38-for-1 Stock Split

Ticker: RGC · Form: 6-K · Filed: 2025-06-17T00:00:00.000Z

Sentiment: neutral

Topics: stock-split, corporate-action

TL;DR

Regencell did a 38-for-1 stock split, no name/symbol change.

AI Summary

Regencell Bioscience Holdings Limited announced a 38-for-one forward stock split on June 2, 2025, effective for shareholders of record on that date. This split was distributed as a stock bonus, meaning shareholders received 37 additional shares for every share they owned. The company's name, CUSIP, and trading symbol remain unchanged.

Why It Matters

A stock split can make shares more accessible to a wider range of investors by lowering the per-share price, potentially increasing liquidity.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a stock split, which is a common corporate action with no inherent negative implications.

Key Numbers

Key Players & Entities

FAQ

What was the effective date of the stock split?

The filing states the stock split was announced on June 2, 2025, and was effective for shareholders of record on that date.

How was the stock split implemented?

The stock split was implemented as a stock bonus, where shareholders received 37 additional shares for every share held on the record date.

Will Regencell's name or trading symbol change after the split?

No, the filing explicitly states there are no changes to the Company's name, CUSIP, or current trading symbol in connection with the forward stock split.

What is the purpose of a forward stock split?

While not explicitly stated as a purpose in this filing, forward stock splits are typically done to make shares more affordable and accessible to a broader investor base.

What is the filing type and its purpose?

This is a Form 6-K, which is a report of foreign private issuers required to be filed with the SEC for the month of June 2025, providing current information not otherwise required to be filed on a registration statement.

From the Filing

0001213900-25-054936.txt : 20250617 0001213900-25-054936.hdr.sgml : 20250617 20250617060827 ACCESSION NUMBER: 0001213900-25-054936 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250617 FILED AS OF DATE: 20250617 DATE AS OF CHANGE: 20250617 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regencell Bioscience Holdings Ltd CENTRAL INDEX KEY: 0001829667 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: E9 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40617 FILM NUMBER: 251051770 BUSINESS ADDRESS: STREET 1: 11/F FIRST COMMERCIAL BUILDING STREET 2: 33-35 LEIGHTON ROAD, CAUSEWAY BAY CITY: HONG KONG STATE: K3 ZIP: 999077 BUSINESS PHONE: 852 2155 0823 MAIL ADDRESS: STREET 1: 11/F FIRST COMMERCIAL BUILDING STREET 2: 33-35 LEIGHTON ROAD, CAUSEWAY BAY CITY: HONG KONG STATE: K3 ZIP: 999077 6-K 1 ea0245816-6k_regencell.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-40617 Regencell Bioscience Holdings Limited (Registrant’s Name) 9/F Chinachem Leighton Plaza 29 Leighton Road Causeway Bay, Hong Kong (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Forward Stock Split Regencell Bioscience Holdings Limited (the “Company”) has effected a 38-for-one forward stock split paid in the form of a stock bonus (the receipt of 37 additional shares for every share held on the record date) that it announced on June 2, 2025. There are no changes to the Company’s name, CUSIP or current trading symbol in connection with the forward stock split. No action is required by shareholders in connection with the forward stock split. Shareholders who hold their shares through a brokerage account will have their shares automatically adjusted to reflect the forward stock split. Registered shareholders will receive their additional shares through the Company’s transfer agent. Exhibit No. Description 99.1 Press Release, dated June 17, 2025 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 17, 2025 Regencell Bioscience Holdings Limited By: /s/ Yat-Gai Au Name: Yat-Gai Au Title: Chief Executive Officer and Chairman of the Board of Directors 2 EX-99.1 2 ea024581601ex99-1_regencell.htm PRESS RELEASE, DATED JUNE 17, 2025 Exhibit 99.1 Regencell Bioscience Holdings Limited Announces the Forward Stock Split is Effected HONG KONG, June 17, 2025 – Regencell Bioscience Holdings Limited (Nasdaq: RGC) (the “Company”), today announced that the Company has effected a 38-for-one forward stock split paid in the form of a stock bonus (the receipt of 37 additional shares for every share held on the record date) that it announced on June 2, 2025. There are no changes to the Company’s name, CUSIP or current trading symbol in connection with the forward stock split. No action is required by shareholders in connection with the forward stock split. Shareholders who hold their shares through a brokerage account will have their shares automatically adjusted to reflect the forward stock split. Registered shareholders will receive their additional shares through the Company’s transfer agent. About Regencell Bioscience Holdings Limited We are an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention

View on Read The Filing